Per Blom

KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.

SBL Vaccin AB manufactures and distributes vaccines. Its products are used for the treatment of polio, diarrhoea, and cholera diseases. The company distributes products to the healthcare centers, hospitals, schools, and industrial healthcare units. SBL Vaccin was founded in 1957 and is located in Solna, Sweden.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.

STI Technologies Ltd. provides marketing solutions to the health care industry. The firm's SmartTechnology platform allows stakeholders-manufacturers, pharmacies, prescribers, and payers to optimize their patient relationships. It offers solutions for pre-launch planning, brand adoption, market uptake, revenue optimization, retention and adherence, and loss of exclusivity. The company was founded by William B. Adams and Gregory Patey in 2001 and is headquartered in Halifax, Canada.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Goesch Pharma Pte Ltd. is a Singaporean company that wholesales pharmaceutical products. The private company is based in Singapore, Singapore.

Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden.

Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.

XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.

Simplexia AB is a company based in Gothenburg, Sweden that aims to launch the first vaccine for the treatment and prevention of genital herpes. The Swedish company is driven by the goal to curtail and treat infection with herpes simplex virus (HSV), one of the world's most prevalent sexually transmitted diseases. The team at Simplexia is composed of experts in pharmaceutical development, including Prof. Jan-Åke Liljeqvist and the Department of Virology at the Sahlgrenska Academy. The vaccine is based on research that showed glycoproteins from HSV-1 and 2, when administered as a vaccine, are highly immunogenic and provide protection in mouse models.

EyeSense GmbH develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. It is developing two different diagnostic systems: An ophthalmic sensor which-once inserted on the eye-can be read out optically as frequently as wanted, without any pain and a continuous sensor, to be worn on the abdomen or upper arm. The firm with its innovative sensor technology able to offer two products that addresses different needs in blood glucose monitoring which are Continuous Glucose Sensor and Eye Sensor. The company was founded in 2006 and is headquartered in Großostheim, Germany.

Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022.

Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.

Airsonett AB is a holding company that is engaged in the research and development of a non-pharmaceutical treatment for asthma. Its product Airsonett is based on temperature controlled Laminar Airflow technology that creates a radically reduced allergen exposure in the breathing zone for treatment of asthma, allergic rhinitis, and atopic eczema. The company was founded by Jan Tommy Lennart Hedberg, Jan Kristensson, and Dan Kristensson in 2000 and is headquartered in Ängelholm, Sweden.

SEB Venture Capital (SEB Venture Capital) is a venture capital subsidiary of Skandinaviska Enskilda Banken AB founded in 1995. The firm is headquartered in Stockholm, Sweden.

Avidicare AB operates as a medical device company. It specializes in the management of airborne bacteria and virus pollution at hospitals. The firm provides Opragon, a ventilation system for reduction of airborne bacterial contamination in various hospital environments primarily for infection sensitive surgery. The company offers Opragon for preparation rooms, operating theaters, and hybrid rooms; and air curtains and external air showers. Avidicare was founded in 2010 and is headquartered in Lund, Sweden.

Neoventa Medical AB develops and markets monitoring and management tools for neonatal healthcare. Its products include Stan S31, Stan Viewer Live, Stan Viewer, Stan Method, and Goldtrace. The company was founded in 1997 and is headquartered in Mölndal, Sweden.